<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620591</url>
  </required_header>
  <id_info>
    <org_study_id>UHL27823/06/28/2018</org_study_id>
    <nct_id>NCT03620591</nct_id>
  </id_info>
  <brief_title>Lidocaine and Analgesia After Laparoscopic Cholecystectomy</brief_title>
  <official_title>Intraoperative Use of Lidocaine and Postoperative Analgesia After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larissa University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larissa University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how effective is the intraoperative use of lidocaine
      to attenuate postoperative pain and opioids consumption after laparoscopic cholecystectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute postoperative pain may predict the development of chronic pain.Recently, the analgesic
      effect of lidocaine, as a part of a multimodal analgesia, has been evaluated in many studies.
      They have shown that lidocaine may have a role in the postoperative pain management, as an
      adjunct.

      Acute postoperative pain after laparoscopic cholecystectomy is complex in nature.
      Postoperative pain is the main complaint and the primary reason for delay discharge after
      laparoscopic cholecystectomy.The study includes patients undergoing laparoscopic
      cholecystectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>24 hours after the procedure</time_frame>
    <description>The total dose of tramadol is calculated as mg and administered intravenously.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Departure of the patient from the recovery room (0hrs)</time_frame>
    <description>Numeric Rate scale 0-10 (0=no pain to 10=worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>6 hrs after the procedure</time_frame>
    <description>Numeric Rate scale 0-10 (0=no pain to 10=worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>12 hrs after the procedure</time_frame>
    <description>Numeric Rate scale 0-10 (0=no pain to 10=worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>24 hrs after the procedure</time_frame>
    <description>Numeric Rate scale 0-10 (0=no pain to 10=worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nausea and Vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of patients who had nausea and vomiting during the first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of sedation and respiratory depression</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of patients who had sedation and respiratory depression during the first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of shoulder pain</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of patients who had shoulder pain during the first24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of headache and dizziness</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of patients who had headache and dizziness during the first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Mean Blood Pressure</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Non-invasive blood pressure measurement by using sphygmomanometer cuff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Heart Rate</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Bradycardia, tachycardia during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depth of anesthesia</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Maintenance of Bispectral index (BIS) values of 40 to 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect related to administration of lidocaine</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of patients who had tremor, dizziness, dysarthria, agitation, hallucinations and drowsiness during the first 24 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Opioid Consumption</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.
Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Intraoperative administration of lidocaine</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intraoperative administration of normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I-II

          -  Age ≥ 18 years old

          -  BMI ≤ 35

        Exclusion Criteria:

          -  Allergy in local anesthetics

          -  History of liver, kidney or heart failure

          -  Existence of chronic pain history or daily analgesics

          -  Psychiatric disorders

          -  Inability to understand pain assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioannis Baloyiannis</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Larissa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chamaidi Sarakatsianou</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Larissa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stavroula Georgopoulou</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Larissa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ioannis Baloyiannis</last_name>
    <phone>+306979339461</phone>
    <email>balioan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Baloyiannis</last_name>
      <phone>+306979339461</phone>
      <email>balioan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Konstantinos Perivoliotis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Tzovaras</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Larissa University Hospital</investigator_affiliation>
    <investigator_full_name>Ioannis Baloyiannis</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Lidocaine</keyword>
  <keyword>Postoperative Pain</keyword>
  <keyword>Opioid consumption</keyword>
  <keyword>Laparoscopic cholecystectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

